Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 133 clinical trials
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

mitoxantrone
serum bilirubin level
refractory acute myeloid leukemia (aml)
secondary acute myeloid leukemia
  • 15 views
  • 07 Nov, 2020
  • 1 location
Cladribine Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

cladribine
remission
cytarabine
idarubicin
  • 14 views
  • 07 Nov, 2020
  • 1 location
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with MGD006 will be safe, tolerable and may …

  • 0 views
  • 31 May, 2021
  • 1 location
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML

  • 0 views
  • 07 Jun, 2021
  • 1 location
AIDA 2000 Guidelines

Prospective use of RT-PCR for PML/RARa might be used to guide a total tehrapy approach in APL, including refined diagnosis, front-line treatment, assessment of response and anticipated salvage therapy for patients who undergo molecular relapse.

serum bilirubin
tretinoin
serum bilirubin level
  • 36 views
  • 25 Jan, 2021
  • 3 locations
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RAR transcript and less than 18 years of age.

  • 0 views
  • 21 Mar, 2021
  • 29 locations
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in) is to rule out excessive toxicity of MBG453, when …

venetoclax
azacitidine
cell transplantation
  • 0 views
  • 24 May, 2021
  • 12 locations
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

ejection fraction
myelodysplastic syndromes
leukapheresis
direct bilirubin
hemolysis
  • 2 views
  • 16 May, 2021
  • 59 locations
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: Safety and tolerability assessments Assessment of infusion

daunorubicin
pegaspargase
refractory acute lymphoblastic leukemia
myeloid leukemia
filgrastim
  • 14 views
  • 14 Jun, 2021
  • 71 locations
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor (GM-CSF) 4 times bi-weekly, then monthly.

cell transplantation
myeloid leukemia
myelodysplastic syndromes
leukemia
colony stimulating factor
  • 53 views
  • 07 Nov, 2020
  • 1 location